Recent blog posts
Ocular Therapeutix™ Initiates its Premier Vital Clinical Study for OTX-TKI
Latest Hotspot
3 min read
Ocular Therapeutix™ Initiates its Premier Vital Clinical Study for OTX-TKI
13 October 2023
Ocular Therapeutix has publicized the start of its premiere primary clinical trial to examine OTX-TKI, a proprietary axitinib intravitreal implant, for tackling wet age-related macular degeneration.
Read →
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment Abilities with Advanced Radioligand Therapies
Latest Hotspot
3 min read
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment Abilities with Advanced Radioligand Therapies
13 October 2023
Eli Lilly along with POINT Biopharma Global, Inc. have declared a final agreement where Lilly will take over POINT, a company specializing in radiopharmaceuticals.
Read →
Alvotech Signs Exclusive License Contract with Kashiv BioSciences for Marketing of Xolair®
Latest Hotspot
3 min read
Alvotech Signs Exclusive License Contract with Kashiv BioSciences for Marketing of Xolair®
13 October 2023
Alvotech along with Kashiv Biosciences LLC have publicized their exclusive licensing accord for AVT23 (also called ADL018).
Read →
ALX Oncology Announces Preliminary Results from Stage 2 Clinical Trial of Evorpacept for HER2-Positive Stomach Cancer
Latest Hotspot
3 min read
ALX Oncology Announces Preliminary Results from Stage 2 Clinical Trial of Evorpacept for HER2-Positive Stomach Cancer
13 October 2023
ALX Oncology Holdings Inc. announced encouraging initial results from Phase 2 of its ASPEN-06 trial. The trial evaluates the use of its CD47 blocker, evorpacept, with trastuzumab, CYRAMZA®, and paclitaxel in treating HER2-positive gastric/gastroesophageal junction cancer patients.
Read →
Boehringer Ingelheim's Adalimumab-adbm is available at low wholesale acquisition cost
Latest Hotspot
3 min read
Boehringer Ingelheim's Adalimumab-adbm is available at low wholesale acquisition cost
12 October 2023
Boehringer Ingelheim revealed that their interchangeable* biosimilar to Humira®, known as Adalimumab-adbm injection, is now available at a low wholesale acquisition cost.
Read →
Caliway's CBL-514 demonstrated superior effectiveness compared to Liposuction
Latest Hotspot
3 min read
Caliway's CBL-514 demonstrated superior effectiveness compared to Liposuction
12 October 2023
Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.
Read →
Rocket Pharmaceuticals reveals that FDA Acceptance of BLA for RP-L201
Latest Hotspot
3 min read
Rocket Pharmaceuticals reveals that FDA Acceptance of BLA for RP-L201
12 October 2023
The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).
Read →
Lassen Therapeutics revealed preclinical findings related to LASN01, an Anti-IL-11 Receptor Antibody for Thyroid Eye Disease
Latest Hotspot
3 min read
Lassen Therapeutics revealed preclinical findings related to LASN01, an Anti-IL-11 Receptor Antibody for Thyroid Eye Disease
12 October 2023
Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.
Read →
Kashiv BioSciences Administers First Patient in Phase III Clinical Trial for ADL018
Latest Hotspot
3 min read
Kashiv BioSciences Administers First Patient in Phase III Clinical Trial for ADL018
12 October 2023
Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.
Read →
Nexcella reveals clinical data from NXC-201 study in Multiple Myeloma
Latest Hotspot
3 min read
Nexcella reveals clinical data from NXC-201 study in Multiple Myeloma
12 October 2023
Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.
Read →
A Phase III trial investigating Novartis' experimental drug, Iptacopan, displayed findings in IgAN patients
Latest Hotspot
3 min read
A Phase III trial investigating Novartis' experimental drug, Iptacopan, displayed findings in IgAN patients
12 October 2023
Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.
Read →
FDA Grants Authorization for Biogen's TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Linked to ACTEMRA®
Latest Hotspot
3 min read
FDA Grants Authorization for Biogen's TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Linked to ACTEMRA®
12 October 2023
Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.
Read →